European Archives - Page 766 of 996 - European Medical Journal

Role of Gut Bacteria as a Parkinson’s Disease Biomarker

BACTERIAL communities in the gut of Parkinson’s patients differ to those of healthy people, potentially providing an early indicator of the…

Improving Patient-Doctor Communication: An Urgent Requirement for Better Patient Outcomes

Several healthcare professionals at the European Respiratory Society (ERS) International Congress 2017 expressed concerns with patient-doctor communication

Liver Disease: A Potential Protective Treatment Opportunity

PROTECTION against alcoholic liver disease may become possible thanks to new research surrounding the protein fibroblast growth factor 21 (FGF21). A…

New Therapeutic Target for Liver Cancer Revealed

PIONEERING research from the University of Maryland, Baltimore, Maryland, USA, has found a potential link between a relatively under-studied gene and…

Urinary Tract Infection Resistant Mutation Identified

A MUTATION altering the effect that levofloxacin, a quinolone antibiotic, has on pathogens causing urinary tract infections (UTI) has been identified by…

Immunotherapy to Advance Prostate Cancer Treatment

A NOVEL immunotherapy strategy for the treatment of prostate cancer using DNA-encoded monoclonal antibodies (DMAb) has shown promising results according…

β-Thalassaemias: Highlights from the European Hematology Association Scientific Working Group (EHA-SWG) Scientific Meeting on Anaemias: Diagnosis and Treatment in the Omics Era

β-thalassaemias are inherited blood disorders caused by a defect in the production of β-globin, giving rise to variable phenotypes.

EMJ Hematology 5 [Suppl 11] 2017

This article comprises a summary of scientific sessions on β-thalassaemia that took place on 2nd–4th February 2017, as part of the European Hematology…

Shuwen Biotech Receives CE Mark for EGFR Mutation PCR Kit for Lung Cancer

Deqing, China, 18 September, 2017 – Shuwen Biotech announced today that it has received CE-IVD marking for its EGFR real time PCR detection kit…

RedHill Biopharma Initiates Promotion of Esomeprazole Strontium Delayed-Release Capsules 49.3 mg in the U.S.

RedHill Biopharma Ltd. announced that it has initiated promotion of Esomeprazole Strontium Delayed-Release (DR) Capsules 49.3 mg1 in the U.S.